BeOne Medicines Ltd. (ONC) operating KPIs
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$370.33−1.23 (-0.33%)
Close on Oct 30, 2026Market cap $42.11BP/E 66.2Yield –
BeOne Medicines tEVIMBRA (tislelizumab, Anti-PD-1) — Global Net Product Revenue ($M) ($M)
Form 10-Q / 10-K Segment Disaggregation Note (XBRL) & MD&A
Latest, FY2025
737
Period ended Dec 31, 2025
Change on a year earlier
+18.8%
621 in FY2024
History
8 years
Since FY2018
Sources
6
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | TEVIMBRA (tislelizumab, Anti-PD-1) — Global Net Product Revenue ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 737 | +18.8% | Form 10-K (filed 2026-02-26) ↗ |
| FY2024 | Dec 31, 2024 | 621 | +15.7% | Form 10-K (filed 2026-02-26) ↗ |
| FY2023 | Dec 31, 2023 | 537 | +26.9% | Form 10-K (filed 2026-02-26) ↗ |
| FY2022 | Dec 31, 2022 | 423 | +65.8% | Form 10-K (filed 2025-02-27) ↗ |
| FY2021 | Dec 31, 2021 | 255 | +56.1% | Form 10-K (filed 2024-02-26) ↗ |
| FY2020 | Dec 31, 2020 | 163 | – | Form 10-K (filed 2023-02-27) ↗ |
| FY2019 | Dec 31, 2019 | 0 | – | Form 10-K (filed 2022-02-28) ↗ |
| FY2018 | Dec 31, 2018 | 0 | – | Form 10-K (filed 2021-02-25) ↗ |
Breakdown
What makes up tevimbra (tislelizumab, anti-pd-1) — global net product revenue ($m)
Cite this data
StockData. (2026). BeOne Medicines TEVIMBRA (tislelizumab, Anti-PD-1) — Global Net Product Revenue ($M) ($M), annual FY2018–FY2025 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/prod_tevimbra_ww
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.